Patients with Essential Thrombocythaemia have an increased prevalence of antiphospholipid antibodies which may be associated with thrombosis

Thrombosis and Haemostasis

Volumn 87, Issue 5, 2002, Pages 802-807

  Harrison, Claire N ^a   Donohoe, S ^a   Carr, P ^a   Dave, M ^a   Mackie, I ^a   Machin, S J ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Antiphospholipid antibodies; ET; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANAGRELIDE; BETA2 GLYCOPROTEIN 1 ANTIBODY; BUSULFAN; CARDIOLIPIN ANTIBODY; CHLORAMBUCIL; HYDROXYUREA; IMMUNOGLOBULIN M ANTIBODY; INTERFERON; PHOSPHOLIPID ANTIBODY; PHOSPHORUS; PROTHROMBIN ANTIBODY;

ADOLESCENT; ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CLINICAL FEATURE; CLONAL VARIATION; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG TOLERABILITY; FEMALE; HUMAN; IMMUNOLOGICAL PARAMETERS; LIFESPAN; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SCHOOL CHILD; STATISTICAL SIGNIFICANCE; THROMBOCYTHEMIA; THROMBOSIS;

EID: 0036247965     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1613087     Document Type: Article

References (30)

1. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis
2. Should a platelet limit of 600 × 10(9)/l be used as a diagnostic criterion in essential thrombocythaemia? An analysis of the natural course including early stages
3. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: High proportion of cases with 17p deletion
4. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia
5. A large proportion of patients with a diagnosis of essential thrombocythaemia do not have a clonal disorder and may be at lower risk of thrombotic complications
6. Clonal hemopoiesis and risk of thrombosis in young female patients with essential thrombocythemia
7. Megakaryocyte and erythroid colony formation in essential thrombocythaemia and reactive thrombocytosis: Diagnostic value and correlation to complications
8. Essential thrombocythaemia and antiphospholipid antibodies
9. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: A final report on diagnostic criteria, survival, and leukemic transition by treatment
10. Epidemiology of the antiphospholipid antibody
11. Frequency and prevention of symptomless deep-vein thrombosis in long-haul flights: A randomised trial
12. Measurement of anti-cardiolipin antibodies by an enzyme-linked immunosorbent assay (ELISA): Standardization and quantitation of results
13. Standardising the anti-cardiolipin antibody test
14. Increased levels of beta 2-glycoprotein-I antigen and beta 2-glycoprotein-I binding antibodies are associated with a history of thromboembolic complications in patients with SLE and primary antiphospholipid syndrome
15. Anti-prothrombin antibodies: Assay conditions and clinical associations in the anti-phospholipid syndrome
16. Which are the best biological markers of the antiphospholipid syndrome?
17. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with SLE
18. Antibodies to prothrombin imply a risk of myocardial infarction in middle aged men
19. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: A four-year prospective study from the Italian Registry
20. Antiphospholipid antibodies: Prevalence, clinical significance and correlation to cytokine levels in acute myeloid leukemia and non-Hodgkin's lymphoma
21. Antiphospholipid antibodies: Their prevalence, clinical significance and correlation with cytokine levels in acute myeloid leukemia and non-Hodgkin's lymphoma
22. Electrokinetic behaviour and surface sialic acid status of blood platelets in essential thrombocythaemia (ET)
23. Increased circulating platelet-leukocyte complexes and platelet activation in patients with antiphospholipid syndrome (APS), systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA)
24. Increased platelet surface expression of P-selectin and thrombospondin as markers of platelet activation in essential thrombocythaemia
25. Increased circulating platelet-leukocyte aggregates in myeloproliferative disorders is correlated to previous thrombosis, platelet activation and platelet count
26. Thromboxane-dependent platelet activation in vivo precedes arterial thrombosis in thrombocythaemia: A rationale for the use of low-dose aspirin as an antithrombotic agent
27. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythaemia and polycythemia vera
28. Anti-endothelial cell antibodies in primary antiphospholipid syndrome and SLE: Patterns of reactivity with membrane antigens on microvascular and umbilical venous cell membranes
29. Infections and antiphospholipid antibodies
30. Guidelines on the investigation and management of the antiphospholipid syndrome